Patient | Age | Sex | Diagnosis | State | Titre | Spec. | BVAS | CRP | VDI | WBC | Immunosuppressive treatment at time of analysis |
---|---|---|---|---|---|---|---|---|---|---|---|
1 | 28 | f | WG | N | >640 | Pr3 | 33 | 190 | 0 | 14.4 | no |
Q | 40 | Pr3 | 0 | <3 | 2 | 6.9 | aza 150 mg + pred 10 mg | ||||
2 | 63 | m | WG | N | >640 | Pr3 | 39 | 149 | 2 | 11.5 | no |
Q | 80 | Pr3 | 0 | <3 | 2 | 6.5 | pred 12.5 mg + CP 75 mg | ||||
3 | 85 | m | WG | N | 160 | Pr3, HLE | 27 | 99 | 1 | 8.0 | no |
4 | 36 | f | WG | N | 80 | Pr3 | 8 | 5 | 0 | 7.6 | no |
5 | 38 | f | WG | R | >640 | Pr3 | 17 | 32 | 5 | 6.0 | CP 75 mg, pred 20 mg |
6 | 56 | m | WG | R | 160 | Pr3 | 7 | 13 | 3 | 6.0 | no |
7 | 35 | m | WG | R | 160 | Pr3 | 17 | 166 | 0 | 15.7 | pred 20 mg |
Q | 20 | Pr3 | 0 | 11 | 1 | 7.5 | pred 2.5 mg + aza 150 mg | ||||
8 | 63 | m | WG | R | 320 | Pr3 | 11 | 47 | 2 | 4.4 | no |
Q | 20 | Pr3 | 0 | 44 | 3 | 8.7 | pred 10 mg | ||||
9 | 76 | f | WG | R | 160 | MPO | 9 | 108 | 7 | 7.5 | no |
10 | 49 | m | WG | R | 80 | Pr3 | 6 | 4 | 1 | 6.8 | no |
Q | 40 | Pr3 | 0 | 4 | 2 | 6.8 | no | ||||
11 | 56 | f | WG | N | 320 | Pr3 | 19 | 55 | 0 | 18.6 | no |
Q | 20 | Pr3 | 0 | 3 | 1 | 8.0 | pred 10 mg + CP 100 mg | ||||
12 | 75 | m | WG | R | 160 | Pr3, MPO | 7 | 17 | 2 | 5.8 | no |
Q | 40 | Pr3, MPO | 0 | 8 | 2 | 10.5 | pred 7.5 mg | ||||
13 | 63 | f | WG | R | 80 | HLE | 3 | 8 | 2 | 5.2 | pred 5 mg + aza 100 mg |
14 | 48 | f | WG | N | 320 | Pr3 | 20 | 118 | 0 | 13.4 | no |
Q | 0 | Pr3 | 0 | <3 | 0 | 4.1 | aza 125 mg + pred 20 mg | ||||
15 | 54 | f | WG | R | 80 | Pr3 | 1 | 92 | 3 | 12.4 | no |
16 | 51 | f | WG | N | >640 | MPO, HLE | 19 | 22 | 0 | 3.6 | no |
17 | 27 | m | WG | N | 320 | Pr3, LF | 15 | 40 | 0 | 9.4 | no |
Q | 40 | LF | 0 | 52 | 1 | 9.7 | pred 20 mg + aza 150 mg | ||||
18 | 44 | m | WG | N | 320 | LF | 11 | 5 | 0 | 5.2 | no |
Q | 80 | LF | 0 | 5 | 2 | 8.1 | pred 32.5 mg + CP 50 mg | ||||
19 | 79 | f | WG | N | 320 | Pr3 | 31 | 81 | 0 | 8.9 | no |
20 | 23 | f | WG | R | 320 | MPO | 10 | <3 | 2 | 4.9 | aza 75 mg |
21 | 72 | f | WG | R | 160 | MPO | 12 | <3 | 2 | 7.8 | no |
22 | 25 | f | WG | N | 40 | Pr3 | 20 | 105 | 0 | 13.1 | no |
23 | 48 | m | WG | R | 80 | Pr3 | 13 | 20 | 2 | 5.1 | no |
24 | 69 | m | WG | N | 320 | Pr3 | 28 | 23.0 | 0 | 178 | no |
aza, azathioprine; CRP, C reactive protein (mg/l); CP, cyclophosphamide; HLE, human leucocyte elastase; MPO, myeloperoxydase; N, newly developed disease; nt, not tested; pred, prednisolone; Pr3, proteinase 3; Q, Quiescent disease; R, relapse; spec., ANCA specificity; titre, ANCA titre; WG, Wegener’s granulomatosis; WBC, white blood cell count (×109/l).